Biogen confirms Icahn ally is on board - Houston Business Journal:

http://www.gite-posada.com/larrazet.html
Shareholders were to elect four directors at the Biogen was pushing for the reelection of all ofthe company’es existing directors, while Icahn was anglingt to seat four new director. According to Biogej Idec, shareholders appear to have reelecte current directors Robert Pangia andWilliam D. Young, and electef Icahn ally Alexander Denner. Biogen Idec official s say the vote for the fourtj seat is too closeto call. Biogen said the compant will rely on the tabulation of voteds by its independent inspectorof elections, IVS Associates, befored announcing the remaining director to serve on the board. Bruce R.
Ross, Biogen Idec’s said, “We welcome our new directorr to the board and look forward to working togethe to build on our strong tracok record ofdelivering value. While we await the outcomse of the vote for the remaining we would like to express our gratituder for the support ofour stockholders.” Icahn, in a filingy with the Securities and Exchange Commission, accused the compant of preventing the votes cast from being counted. “If the boarde is successful, Richard Mulligan, a prominent scientist and physician, may be kept from legitimatelyg being elected tothe board.
” Mulligan is the Mallinckrodg Professor of Genetics at Harvard Medical School and director of the Harvarde Gene Therapy Initiative, according to Harvard University’ws Web site. Biogen said shareholderz rejected severalof Icahn’s othetr proposals, including moving the company’ws incorporation from Delaware to Northj Dakota, a move Icahn said woule give more power to shareholders. Biogen officials said it appearz that stockholders also rejected a proposal by Icahhn to limit the size of the boarf to13 directors. Biogen officials now have the powere to enlarge the board as theysee fit.
Icahnj is best known for unsuccessfully pushing BiogenIdec BIIB) to sell itself in 2008. Last shareholders elected the company’sa nominees over the slate of investors put up by Biogen Idec’s (NASDAQ: stock was trading at $53.17 in afternoon trading Thursday, down from the previouas day’s close of $53.43 a share.